Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
Artificial intelligence also played a large role in discovering how this intricate network of muscle fibers can influence health, experts explained in Nature.
Work-related stress is associated with an increased risk of peripheral artery disease (PAD), according to a new study published in the Journal of the American Heart Association.